Impacts

The IDI provides funding to catalyze interdisciplinary infectious disease research, including trainee research, and to fund other strategic initiatives through its various funding mechanisms. The significant impacts of these funding mechanisms are highlighted below.

Internal Funding Mechanism Type

Interdisciplinary Research Seed Grants

Thematic Program Research Support (HDMB, AMR)

Trainee Transformative Grants

Targeted Investments

Investment

$810K FY18-24

$42K FY20-24

$550K FY18-24

Return on Investment (ROI)

38 grants submitted
$31M in extramurally funded grants (19 awards, including clinical trial)
8 Patents (Pending or Issued)
2 Biotech Startup Companies

16 grants submitted (5 awards)
20 presentations, 3 manuscripts
2 professional awards/fellowships
2 patents (pending or issued)

Programmatic development resulting in a NIH T32, designation as a CFF Research Development Center, GeoHAI software, slect agents research, etc.

Research expenditures for total IDI faculty (core plus affiliate) showed around 13 percent growth in FY24 ($99.3M compared to $86.5M in FY23).

FY24 research expenditures by total IDI faculty were 6.85 percent of total university expenditures for FY23 (1.45B). Data for total university research expenditures is not yet available for FY24.

Research Expenditures for core IDI faculty were $62.6M which is around 63 percent of total IDI faculty research expenditures. Core IDI faculty members were based on the FY23 Membership List.